Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | STK4 | Q13043 | 5/20 | 0.38 |
| ▸ | STK3 | Q13188 | 5/20 | 0.38 |
| ▸ | SIK2 | Q9H0K1 | 5/20 | 0.38 |
| ▸ | STK26 | Q9P289 | 5/20 | 0.38 |
| ▸ | STK24 | Q9Y6E0 | 5/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.37 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.37 |
| ▸ | PAK3 | O75914 | 3/20 | 0.37 |
| ▸ | PAK2 | Q13177 | 3/20 | 0.37 |
| ▸ | PAK4 | O96013 | 2/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041869 | 0.87 | CDK2 (0.42) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL15787838 | 0.83 | SIK2 (0.45) | STK4STK3SIK2STK26STK24 | |
| SCHEMBL15041878 | 0.78 | PAK4 (0.38) | CDK2STK4STK3SIK2STK26 | |
| SCHEMBL14682028 | 0.76 | CDK4 (0.42) | CDK2STK4STK3SIK2STK26 | |
| SCHEMBL15041885 | 0.76 | TNK2 (0.42) | PAK1PKN1PAK4TNK2RIPK2 | |
| SCHEMBL15041894 | 0.75 | RIPK2 (0.41) | RIPK2ACVR1NOD2 | |
| SCHEMBL14693007 | 0.75 | RIPK2 (0.40) | STK4STK3SIK2STK26STK24 | |
| SCHEMBL13553620 | 0.74 | CDK4 (0.46) | CCNE1CDK2PAK1PKN1PAK3 | |
| SCHEMBL13553608 | 0.74 | RIPK2 (0.38) | CDK2STK4STK3SIK2STK26 | |
| SCHEMBL15041475 | 0.74 | RIPK2 (0.38) | CDK2STK4STK3SIK2STK26 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | CCNT1 4269/4885CCNK 1716/4885CCNE1 3907/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CCNT1 2002/4885CCNK 757/4885CCNE1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.